Clinical trials: Pneumonia, Pneumococcal
Pneumonia, Pneumococcal
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
- Trial name
- NCT04278248
- Testing
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,940 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Bacterial
Prevalence and Serotype of Streptococcus Pneumoniae Hospitalized Adult With Community-Acquired Pneumonia
Streptococcus Pneumoniae is one of the etiology in severe CAP and accounts for about 60-75% of cases and is likely to be the leading cause of unknown etiologic pneumonia.
- Trial name
- HACAP (NCT05173727)
- Where
- Indonesia
- Volunteers
- 355 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Pneumonia, Pneumococcal, Pneumococcal Infections
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
- Conditions
- Pneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine
- Trial name
- CAPITA (NCT00744263)
- Testing
- VACCINE: 13-valent pneumococcal conjugate vaccine
- Where
- 159 sites in Netherlands
- Volunteers
- 84,496 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Meningitis
Lebanese Interhospital Pneumococcal Surveillance Program
Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection.
- Conditions
- Pneumonia, Meningitis, Sepsis, Bacteremia
- Trial name
- LIPSP (NCT00901602)
- Where
- Lebanon
- Volunteers
- 700 people
- Sponsor
- American University of Beirut Medical Center
The Effect of Milk Components on the Response to Pneumococcal Vaccines in the Elderly
The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens
The purpose of this study is to determine if the daily use of a certain amount and type of milk component for 2 months provides a significant stimulation to the immune system and specifically increases the chances of being…
- Trial name
- NCT01626300
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Pneumonia, Pneumonia - Bacterial
Urine Pneumococcal Antigen Project
Background: Pneumonia caused by the bacteria Streptococcus pneumoniae is a leading cause of death among children under five years of age, especially in sub-Saharan Africa.
- Trial name
- UPAP (NCT07181200)
- Where
- Malawi
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant…
- Trial name
- NCT05844423
- Testing
- 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24
- Where
- 32 sites in United States
- Volunteers
- 802 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumonia
A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine
Investigators in the Division of Infectious Diseases and the Division of Hospital Medicine of The George Washington University Medical Center are carrying out a study to determine if hospitalized patients receiving the polyvalent…
- Trial name
- NCT00955851
- Testing
- Pre and post vaccination titers
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- George Washington University
Community-acquired Pneumonia, Streptococcus Pneumoniae Infection
Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala
This prospective case-control study aims to evaluate the utility and establish laboratory thresholds for a multi-serotype urine antigen test for the diagnosis of pneumococcal community acquired pneumonia in children 5 years of…
- Trial name
- NCT03696303
- Testing
- Urinary antigen detection assay
- Where
- 3 sites in Guatemala
- Volunteers
- 959 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Streptococcus Pneumonia, Haemophilus Influencae
Etiology of Community Acquired Pneumonia
The proposed study aims to provide current information, etiology and outcome of community-acquired pneumonia (CAP), risk factors for for CAP in isolates of Streptococcus pneumoniae and Haemophilus influencae, Mycoplasma…
- Conditions
- Streptococcus Pneumonia, Haemophilus Influencae, Mycoplasma Pneumonia, Chlamydia Pneumonia
- Trial name
- CAP (NCT00471757)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Pneumonia, Pneumococcal
Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)
To explore a further dimension of susceptibility to disease, the investigators tested the hypothesis that natural variation exists in the rapidity of IgG responses following exposure to pneumococcal polysaccharides, and that…
- Trial name
- NCT03460730
- Testing
- Pneumovax
- Where
- Kenya
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Streptococcus Pneumonia, Otitis Media
Pneumococcal Carriage and Serotype Distribution in Children With Otitis Media in Malaysia.
The purpose of this research is to conduct a multi-center prospective surveillance study focusing upon pneumococcal carriage and serotype epidemiology in patients with otitis media (OM).The data generated will be crucial…
- Trial name
- OM (NCT05429541)
- Where
- 2 sites in Malaysia
- Volunteers
- 360 people
- Sponsor
- IMU University, Malaysia
Pneumonia
Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA
In this Phase I clinical study, three recombinant, avirulent Salmonella Typhi (RASV) strains each expressing the Streptococcus pneumoniae surface protein, PspA, will be compared as live biological vaccine vectors to evaluate safe…
- Trial name
- NCT01033409
- Testing
- Salmonella Typhi-vectored pneumonia vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Infections, Streptococcal
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ given at 12-18 mo of age to children primed with either…
- Trial name
- NCT00370396
- Testing
- Synflorix, Prevenar, Infanrix hexa
- Where
- 35 sites in Finland, France and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections, Pneumonia, Pneumococcal
Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)
The primary objectives are to evaluate the safety and tolerability of V114 and to compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) across 3 different lots of V114.
- Trial name
- PNEU-TRUE (NCT03950856)
- Testing
- V114, Prevnar 13™
- Where
- 55 sites in United States, Australia and 4 more
- Volunteers
- 2,340 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Community-Acquired Pneumonia (CAP)
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia…
- Trial name
- NCT06782282
- Where
- United States
- Volunteers
- 22,234,435 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial
Modulation of Steroid Immunosuppression by Alveolar Efferocytosis
The long-term goals of this study are (a) to understand the biological underpinnings for the increased incidence of community-acquired pneumonia in patients with chronic obstructive pulmonary disease (COPD) who are treated with…
- Trial name
- NCT03034642
- Testing
- Bronchoscopy with bilateral bronchoalveolar lavages
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VA Ann Arbor Healthcare System
Pneumonia, Meningitis
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
The study aims to evaluate the safety and immunogenicity of the 10-valent and 13-valent pneumococcal conjugate vaccines when administered in an accelerated schedule in Papua New Guinean children, who experience early dense upper…
- Conditions
- Pneumonia, Meningitis, Bacteraemia, Sepsis
- Trial name
- PCV1103 (NCT01619462)
- Testing
- Prevenar 13 and Synflorix
- Where
- Papua New Guinea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Influenza and Pneumonia
Health Economic Evaluation of Influenza and Pneumococcal Vaccination in COPD Patients
This is a multicenter, open-label, blank-controlled clinical trial to evaluate the impact of influenza vaccination and pneumococcal vaccination on disease progression and medical burden in COPD patients aged 45-80 years, as well…
- Trial name
- NCT07640841
- Testing
- Influenza Vaccine Group, Pneumococcal Vaccine Group
- Volunteers
- 7,000 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention